Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesLymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Mariette X et al. – The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar as that expected for such patients with severe inflammatory diseases. However, some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Methods- National prospective registry (RATIO) from 2004 to 2006
- All cases of lymphoma in French patients receiving anti-TNF therapy, whatever the indication collected
- Case-control analysis including 2 controls treated with anti-TNF per case and an incidence study of lymphoma with French population used as reference
- Collected 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B-cell and 5 T-cell), 5 Hodgkin’s lymphoma (HL) and 2 Hodgkin’s-like lymphoma
- Epstein-Barr virus (EBV) detected in 2 of 2 Hodgkin’s-like lymphoma, 3 of 5 HL and 1 NHL
- Patients receiving adalimumab or infliximab had higher risk than those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8)
- Exposure to adalimumab or infliximab versus etanercept independent risk factor for lymphoma in case-control study: odds ratio=4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively
- Sex and age- adjusted incidence rate of lymphoma was 42.1 per 100,000 patient-y
- Standardized incidence ratio (SIR) 2.4 (95% confidence interval [CI] 1.7–3.2)
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Sponsor
Article Search
Sponsor